Transgene SA
TRGNF
$0.70
-$0.89-55.98%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -97.07% | -97.02% | -- |
| Total Other Revenue | 43.83% | 32.22% | 50.12% | 53.14% | -30.31% |
| Total Revenue | 43.83% | 32.22% | -5.44% | -3.53% | -30.31% |
| Cost of Revenue | 22.45% | 12.57% | 33.17% | 35.85% | -2.04% |
| Gross Profit | -16.50% | -7.10% | -44.30% | -47.20% | -10.41% |
| SG&A Expenses | -12.49% | -19.54% | -15.11% | -13.40% | 38.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 55.91% | 59.43% | 59.15% | 62.35% | -109.99% |
| Total Operating Expenses | 14.94% | 5.66% | 23.13% | 25.61% | -2.32% |
| Operating Income | -9.05% | -0.26% | -29.24% | -31.84% | -6.38% |
| Income Before Tax | -23.42% | -13.46% | -169.44% | -174.85% | -2.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.42% | -13.46% | -169.44% | -174.85% | -2.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.42% | -13.46% | -169.44% | -174.85% | -2.51% |
| EBIT | -9.05% | -0.26% | -29.24% | -31.84% | -6.38% |
| EBITDA | -8.91% | -0.12% | -29.84% | -32.46% | -8.10% |
| EPS Basic | 6.03% | 13.54% | -106.45% | -110.43% | -1.38% |
| Normalized Basic EPS | 6.01% | 13.54% | -107.55% | -112.15% | -1.29% |
| EPS Diluted | 3.19% | 10.95% | -108.80% | -112.75% | -0.92% |
| Normalized Diluted EPS | 6.01% | 13.54% | -107.55% | -112.15% | -1.29% |
| Average Basic Shares Outstanding | 31.26% | 31.26% | 30.57% | 30.57% | 1.16% |
| Average Diluted Shares Outstanding | 31.26% | 31.26% | 30.57% | 30.57% | 1.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |